6,338 Shares in Edwards Lifesciences Corporation $EW Bought by Csenge Advisory Group

Csenge Advisory Group bought a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, Holdings Channel.com reports. The firm bought 6,338 shares of the medical research company’s stock, valued at approximately $573,000.

A number of other institutional investors have also recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at about $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences in the second quarter worth approximately $1,274,082,000. Norges Bank acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth approximately $803,686,000. Deutsche Bank AG bought a new stake in Edwards Lifesciences in the second quarter valued at approximately $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 2.4%

NYSE:EW opened at $90.02 on Friday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $51.83 billion, a price-to-earnings ratio of 51.74, a PEG ratio of 2.32 and a beta of 0.85. The firm has a fifty day simple moving average of $89.12 and a two-hundred day simple moving average of $84.63.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The business had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period in the previous year, the company posted $0.67 EPS. The firm’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Royal Bank Of Canada raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research report on Friday, April 24th. Citigroup boosted their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Robert W. Baird increased their price target on Edwards Lifesciences from $85.00 to $87.00 and gave the stock a “neutral” rating in a report on Friday, April 24th. Finally, Evercore reissued an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Activity

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total transaction of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares in the company, valued at approximately $8,521,962.62. The trade was a 19.01% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total transaction of $56,966.57. Following the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 25,570 shares of company stock worth $2,219,390 over the last quarter. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.